Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma

Table 1 Clinical characteristics of seven patients with CLE at initial presentation

Age	Sex	Symptoms	ABGA (PaO2 mmHg)	Shunt of evidence	Course of TACE (was occurred CLE)	Reference
52	Male	Headache
		Mental change	74.7	(-)	2	8
		Motor weakness
58	Male	Visual loss
		Headache
		Chest pain	70.2	(-)	1	8
		Shortness of breath
56	Male	Dyspnea	66	ND	3	8
81	Female	Asleep, Tachypnea	ND	ND	1.2	9
		Motor weakness
76	Male	Mental change	Hypoxia	ND	16	7
		Hypoxia
70	Female	Mental change	ND	(-)	1	10
		Disorientation
62	Female	Asleep	56.6	(-)	3	Present case

ND: Not described.

Table 2 Outcomes and associated risk factors for TACE in the patients with CLE

Doses of lipiodol (mL)	Tumor size	Pulmonary embolism	Injection artery of lipiodol	Recovery time (wk)	Reference
35	ND	(+)	ND	3	8
8	ND	(+)	ND	3	8
ND	ND	(+)	ND	2	8
15	10 cm × 14 cm	(+)	RIPA, RMA	2	9
ND	Large	(+)	RIPA	6	7
			Hepatic proper artery
			Epicholedocal artery
12	Large	(-)	RCA, RHA, MHA	Death	10
30	10 cm × 15 cm	(+)	RIPA, RHA	6	Present case

ND: Not described; RCA: Renal capsular artery; RHA: Right hepatic artery; MHA: Middle hepatic artery; RIPA: Right inferior phrenic artery; RMA: Right mammary artery.